

DTap Pediatric Vaccine Insert, Daptacel by Sanofi Pasteur

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use DAPTACEL safely and effectively. See full prescribing information for DAPTACEL.

DAPTACEL (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) Suspension for Intramuscular Injection

Initial U.S. Approval: 2002

RECENT MAJOR CHANGES

Warnings and Precautions (5.8) 10/2013

INDICATIONS AND USAGE

DAPTACEL is a vaccine indicated for active immunization against diphtheria, tetanus and pertussis as a five-dose series in infants and children 6 weeks through 6 years of age (prior to 7th birthday). (1)

DOSAGE AND ADMINISTRATION

The five-dose immunization series consists of a 0.5 mL intramuscular injection administered at 2, 4, 6 and 15-20 months of age, and at 4-6 years of age. (2.1, 2.2)

DOSAGE FORMS AND STRENGTHS

Suspension for injection, supplied in single-dose (0.5 mL) vials (3)

CONTRAINDICATIONS

Severe allergic reaction (e.g., anaphylaxis) after a previous dose of any diphtheria toxoid, tetanus toxoid, or pertussis-containing vaccine, or any component of DAPTACEL. (4.1)
Encephalopathy within 7 days of a previous pertussis-containing vaccine with no other identifiable cause. (4.2)

Progressive neurologic disorder until a treatment regimen has been established and the condition has stabilized. (4.3)

WARNINGS AND PRECAUTIONS

Carefully consider benefits and risks before administering DAPTACEL to persons with a history of:
- fever $\geq 40.5^{\circ}\text{C}$ (105°F), hypotonic-hyporesponsive episode (HHE) or persistent, inconsolable crying lasting ≥ 3 hours within 48 hours after a previous pertussis-containing vaccine. (5.2)
- seizures within 3 days after a previous pertussis-containing vaccine. (5.2)

- If Guillain-Barré syndrome occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, the risk for Guillain-Barré syndrome may be increased following DAPTACEL. (5.3)
- For infants and children with a history of previous seizures, an antipyretic may be administered (if the dosage recommended in its prescribing information) at the time of vaccination with DAPTACEL and for the next 24 hours. (5.4)

- Apnea following intramuscular vaccination has been observed in some infants born prematurely. The decision about when to administer an intramuscular vaccine, including DAPTACEL, to an infant born prematurely should be based on consideration of the individual infant's medical status and the potential benefits and possible risks of vaccination. (5.7)
- Syncope (fainting) has been reported following vaccination with DAPTACEL. Procedures should be in place to prevent falling injury and manage syncopal reactions.

ADVERSE REACTIONS

- Rates of adverse reactions varied by dose number, with systemic reactions most frequent following doses 1-3 and injection site reactions most frequent following doses 4 and 5. Systemic reactions that occurred in $>50\%$ of subjects following any dose included fussiness/irritability, inconsolable crying, and decreased activity/lethargy. Fever $\geq 38.0^{\circ}\text{C}$ occurred in 6-16% of US subjects, depending on dose number. Injection site reactions that occurred in $>30\%$ of subjects following any dose included tenderness, redness and increase in arm circumference. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Sanofi Pasteur Inc., at 1-800-822-246 (1-800-VACCINE) or VAERS at 1-800-822-7967 and <http://vaers.hhs.gov>.

DRUG INTERACTIONS

- Do not mix with any other vaccine in the same syringe or vial. (7.1)
- Immunosuppressive therapies may reduce the immune response to DAPTACEL. (7.2)

See 17 for PATIENT COUNSELING INFORMATION

Revised: [10/2013]

FULL PRESCRIBING INFORMATION: CONTENTS*

INDICATIONS AND USAGE

DOSAGE AND ADMINISTRATION

2.1 Immunization Series

2.2 Administration

DOSAGE FORMS AND STRENGTHS

CONTRAINDICATIONS

4.1 Hypersensitivity

4.2 Encephalopathy

4.3 Progressive Neurologic Disorder

WARNINGS AND PRECAUTIONS

5.1 Management of Acute Allergic Reactions

5.2 Adverse Reactions Following Prior Pertussis Vaccination

5.3 Guillain-Barré Syndrome and Brachial Neuritis

5.4 Infants and Children with a History of Previous Seizures

5.5 Limitations of Vaccine Effectiveness

5.6 Altered Immunocompetence

5.7 Apnea in Premature Infants

5.8 Syncope

ADVERSE REACTIONS

6.1 Data from Clinical Studies

6.2 Data from Post-Marketing Experience

FULL PRESCRIBING INFORMATION:

INDICATIONS AND USAGE

DAPTACEL[®] is a vaccine indicated for active immunization against diphtheria, tetanus and pertussis as a five-dose series in infants and children 6 weeks through 6 years of age (prior to seventh birthday).

DOSAGE AND ADMINISTRATION

Immunization Series

DAPTACEL vaccine is to be administered as a 5-dose series at 2, 4 and 6 months of age (at intervals 6-8 weeks), at 15-20 months of age and at 4-6 years of age. The first dose may be given as early as 6 weeks of age. Four doses of DAPTACEL vaccine constitute a primary immunization course for pertussis. The fifth dose is a booster for pertussis immunization. Three doses of DAPTACEL vaccine constitute a primary immunization course for diphtheria and tetanus. The fourth and fifth doses are boosters for diphtheria and tetanus immunization. [See Clinical Studies (6.1, 6.2)]

7 DRUG INTERACTIONS

- 7.1 Concomitant Administration with Other Vaccines
- 7.2 Immunosuppressive Treatments

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.4 Pediatric Use

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

13 NON-CLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

14.1 Diphtheria

14.2 Tetanus

14.3 Pertussis

14.4 Concomitantly Administered Vaccines

15 REFERENCES

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

4.2 Encephalopathy

Encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) within 7 days of a previous dose of a pertussis-containing vaccine that is not attributable to another identifiable cause is a contraindication to administration of any pertussis-containing vaccine including DAPTACEL vaccine.

4.3 Progressive Neurologic Disorder

Progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy, or progressive encephalopathy is a contraindication to administration of any pertussis-containing vaccine including DAPTACEL vaccine. Pertussis vaccine should not be administered to individuals with such conditions until a treatment regimen has been established and the condition has stabilized.

5 WARNINGS AND PRECAUTIONS

5.1 Management of Acute Allergic Reactions

Epinephrine hydrochloride solution (1:1,000) and other appropriate agents and equipment must be

WARNINGS AND PRECAUTIONS

carefully consider benefits and risks before administering DAPTACEL to persons with a history of: fever ≥40.5°C (105°F), hypotonic-hyposensitive episode (HHE) or persistent, inconsolable crying lasting ≥3 hours within 48 hours after a previous pertussis-containing vaccine. (5.2) seizures within 3 days after a previous pertussis-containing vaccine. (5.2)

- Do not mix with any other vaccine in the same syringe or vial. (7.1)
Immunosuppressive therapies may reduce the immune response to DAPTACEL. (7.2)

See 17 for PATIENT COUNSELING INFORMATION

Revised: [10/2013]

I. PRESCRIBING INFORMATION: CONTENTS*

INDICATIONS AND USAGE

DOSAGE AND ADMINISTRATION

2.1 Immunization Series

2.2 Administration

DOSAGE FORMS AND STRENGTHS

CONTRAINDICATIONS

- 4.1 Hypersensitivity
4.2 Encephalopathy
4.3 Progressive Neurologic Disorder

WARNINGS AND PRECAUTIONS

- 5.1 Management of Acute Allergic Reactions
5.2 Adverse Reactions Following Prior Pertussis Vaccination
5.3 Guillain-Barré Syndrome and Brachial Neuritis
5.4 Infants and Children with a History of Previous Seizures
5.5 Limitations of Vaccine Effectiveness
5.6 Altered Immunocompetence
5.7 Apnea in Premature Infants
5.8 Syncope

ADVERSE REACTIONS

- 6.1 Data from Clinical Studies
6.2 Data from Post-Marketing Experience

II. PRESCRIBING INFORMATION:

INDICATIONS AND USAGE

PTACEL® is a vaccine indicated for active immunization against diphtheria, tetanus and pertussis as a five-dose series in infants and children 6 weeks through 6 years of age (prior to tenth birthday).

DOSAGE AND ADMINISTRATION

1 Immunization Series

PTACEL vaccine is to be administered as a 5 dose series at 2, 4 and 6 months of age (at intervals 6-8 weeks), at 15-20 months of age and at 4-6 years of age. The first dose may be given as early as 6 weeks of age. Four doses of DAPTACEL vaccine constitute a primary immunization series for pertussis. The fifth dose is a booster for pertussis immunization. Three doses of PTACEL vaccine constitute a primary immunization course for diphtheria and tetanus. The fourth and fifth doses are boosters for diphtheria and tetanus immunization. [See Clinical Studies (14.1, 14.2, 14.3).]

PTACEL vaccine should be used as the fifth dose of the DTaP series in children who initially received 4 doses of Pentacel® [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) vaccine, 10µg Pasteur Limited]. Pentacel and DAPTACEL vaccines contain the same pertussis antigens, manufactured by the same process, although Pentacel vaccine contains twice the amount of toxified pertussis toxin (PT) and four times the amount of filamentous hemagglutinin (FHA) DAPTACEL vaccine.

There are not available on the safety and effectiveness of using mixed sequences of DAPTACEL vaccine and DTaP vaccines from different manufacturers for successive doses of the DTaP immunization series. DAPTACEL vaccine may be used to complete the immunization series in infants who have received 1 or more doses of whole-cell pertussis DTP. However, the safety and efficacy of DAPTACEL vaccine in such infants have not been fully demonstrated.

A decision is made to withhold any recommended dose of pertussis vaccine, [see Contraindications (4.2), (4.3) and Warnings and Precautions (5.2)]. Diphtheria and Tetanus toxoids Adsorbed for Pediatric Use (DT) should be administered.

2 Administration

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If either of these conditions is present, the product should not be administered.

When removing the "flip-off" cap, cleanse the vaccine vial stopper with a suitable germicide. Do not remove either the rubber stopper or the metal seal holding it in place. Just before use, shake the vial well until a uniform, white, cloudy suspension results.

Using a sterile needle and syringe and aseptic technique, withdraw and administer a single 0.5 mL dose of DAPTACEL vaccine intramuscularly. Use a separate sterile needle and syringe for each injection. Changing needles between withdrawing the vaccine from the vial and injecting into a recipient is not necessary unless the needle has been damaged or contaminated. In infants younger than 1 year, the anterolateral aspect of the thigh provides the largest muscle mass and is the preferred site of injection. In older children, the deltoid muscle is usually large enough for injection. The vaccine should not be injected into the gluteal area or areas where nerves may be a major nerve trunk.

Do not administer this product intravenously or subcutaneously.

DAPTACEL vaccine should not be combined through reconstitution or mixed with any other vaccine.

DOSAGE FORMS AND STRENGTHS

DAPTACEL vaccine is a suspension for injection in 0.5 mL single dose vials. See Description (11) for a complete listing of ingredients.

CONTRAINDICATIONS

1 Hypersensitivity

A severe allergic reaction (e.g., anaphylaxis) after a previous dose of DAPTACEL vaccine or any other tetanus toxoid, diphtheria toxoid, or pertussis-containing vaccine, or any other component of this vaccine is a contraindication to administration of DAPTACEL vaccine. [See Description (11).] Because of uncertainty as to which component of the vaccine may be responsible, none of the components should be administered. Alternatively, such individuals may be referred to an allergist for evaluation if further immunizations are to be considered.

7 DRUG INTERACTIONS

- 7.1 Concomitant Administration with Other Vaccines
7.2 Immunosuppressive Treatments

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
8.4 Pediatric Use

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

13 NON-CLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

- 14.1 Diphtheria
14.2 Tetanus
14.3 Pertussis
14.4 Concomitantly Administered Vaccines

15 REFERENCES

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

4.2 Encephalopathy

Encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) within 7 days of a previous dose of a pertussis-containing vaccine that is not attributable to another identifiable cause is a contraindication to administration of any pertussis-containing vaccine including DAPTACEL vaccine.

4.3 Progressive Neurologic Disorder

Progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy, or progressive encephalopathy is a contraindication to administration of any pertussis-containing vaccine including DAPTACEL vaccine. Pertussis vaccine should not be administered to individuals with such conditions until a treatment regimen has been established and the condition has stabilized.

5 WARNINGS AND PRECAUTIONS

5.1 Management of Acute Allergic Reactions

Epinephrine hydrochloride solution (1:1,000) and other appropriate agents and equipment must be available for immediate use in case of anaphylactic or acute hypersensitivity reaction occurs.

5.2 Adverse Reactions Following Prior Pertussis Vaccination

If any of the following events occur within the specified period after administration of a whole-cell pertussis vaccine or a vaccine containing an acellular pertussis component, the decision to administer DAPTACEL vaccine should be based on careful consideration of potential benefits and possible risks. [See Dosage and Administration (2.1).]

- Temperature of ≥40.5°C (105°F) within 48 hours, not attributable to another identifiable cause.
Collapse or shock-like state [hypotonic-hyposensitive episode (HHE)] within 48 hours.
Persistent, inconsolable crying lasting ≥3 hours within 48 hours.
Seizures with or without fever within 3 days.

5.3 Guillain-Barré Syndrome and Brachial Neuritis

A review by the Institute of Medicine found evidence for a causal relationship between tetanus toxoid and both brachial neuritis and Guillain-Barré syndrome. If Guillain-Barré syndrome occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, the risk for Guillain-Barré syndrome may be increased following DAPTACEL vaccine.

5.4 Infants and Children with a History of Previous Seizures

For infants or children with a history of previous seizures, an appropriate antipyretic may be administered (in the dosage recommended in its prescribing information) at the time of vaccination with a vaccine containing an acellular pertussis component (including DAPTACEL vaccine) and for the following 24 hours, to reduce the possibility of post-vaccination fever.

5.5 Limitations of Vaccine Effectiveness

Vaccination with DAPTACEL vaccine may not protect all individuals.

5.6 Altered Immunocompetence

If DAPTACEL vaccine is administered to immunocompromised persons, including persons receiving immunosuppressive therapy, the expected immune response may not be obtained. [See Immunosuppressive Treatments (7.2).]

5.7 Apnea in Premature Infants

Apnea following intramuscular vaccination has been observed in some infants born prematurely. The decision about when to administer an intramuscular vaccine, including DAPTACEL, to an infant born prematurely should be based on consideration of the individual infant's medical status and the potential benefits and possible risks of vaccination.

5.8 Syncope

Syncope (fainting) has been reported following vaccination with DAPTACEL. Procedures should be in place to prevent falling injury and manage syncopal reactions.

6 ADVERSE REACTIONS

6.1 Data from Clinical Studies

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a vaccine cannot be directly compared to rates in the clinical trials of another vaccine and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to vaccine use and for approximating rates of those events.



DTaP
pg. 2

Hep B pediatric vaccine by GlaxoSmithKline



inant)]
r Injection

lose is appropriate,
10 years of age and
ge and older. Studies
antibody titers after
ction 2.2 for informa-
odialysis.

Hepatitis B Virus
sure to the hepatitis B
s, persons who experi-
e to the virus) should be
dition to ENGERIX-B
mmunization Practices
rt for HBIG, ENGERIX-B
, and 6 months of 0, 1,

able in the following

filled TIP-LOK® syringes
filled TIP-LOK syringes
age and Handling (16).]

is) after a previous
r to any component of
tion to administration
' Supplied/Storage and

pes of prefilled
tip cap which may
a tip cap and a
ex rubber. Use of these
x-sensitive individuals.
'How Supplied/Storage

tion with administra-
X-B. Syncope can be
such as visual distur-
vements. Procedures
to restore cerebral

for infants weighing
HBSAg negative at the
mmence at chronologi-
ts weighing <2,000 g
of unknown HBsAg
3 immune globulin
t be determined; the
dose in the vaccine
-dose standard regimen
stration (2).]

tion has been observed
about when to admin-
GERIX-B, to infants born
on of the infant's medi-
sible risks of vaccina-
l include consideration
d the high probability of
infants born of mothers
yzed.

Vaccine Reactions
rovider should review
e sensitivity and previ-
allow an assessment
appropriate agents
actions must be immu-
ic reaction occur. [See

manifestations of an
ffects, vaccination
sons with moderate
e at immediate risk of
sAg-positive mothers).

ENERGIX-B®
[Hepatitis B Vaccine (Recombinant)]
Suspension for Intramuscular Injection

5.7 Altered Immunocompetence

Immunocompromised persons may have a diminished immune response to ENGERIX-B, including individuals receiving immunosuppressant therapy.

5.8 Multiple Sclerosis

Results from 2 clinical studies indicate that there is no association between hepatitis B vaccination and the development of multiple sclerosis,³ and that vaccination with hepatitis B vaccine does not appear to increase the short-term risk of relapse in multiple sclerosis.⁴

5.9 Limitations of Vaccine Effectiveness

Hepatitis B has a long incubation period. ENGERIX-B may not prevent hepatitis B infection in individuals who had an unrecognized hepatitis B infection at the time of vaccine administration. Additionally, it may not prevent infection in individuals who do not achieve protective antibody titers.

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a vaccine cannot be directly compared to rates in the clinical trials of another vaccine and may not reflect the rates observed in practice. The most common solicited adverse events were injection site soreness (22%) and fatigue (14%).

In 36 clinical studies, a total of 13,495 doses of ENGERIX-B were administered to 5,071 healthy adults and children who were initially seronegative for hepatitis B markers, and healthy neonates. All subjects were monitored for 4 days post-administration. Frequency of adverse events tended to decrease with successive doses of ENGERIX-B.

Using a symptom checklist, the most frequently reported adverse events were injection site soreness (22%) and fatigue (14%). Other events are listed below. Parent or guardian completed forms for children and neonates. Neonatal checklist did not include headache, fatigue, or dizziness.

Incidence 1% to 10% of Injections: Nervous System Disorders: Dizziness, headache.

General Disorders and Administration Site Conditions:

Fever (>37.5°C), injection site erythema, injection site induration, injection site swelling.

Incidence <1% of Injections: Infections and Infestations: Upper respiratory tract illnesses.

Blood and Lymphatic System Disorders: Lymphadenopathy.

Metabolism and Nutrition Disorders: Anorexia.

Psychiatric Disorders: Agitation, insomnia.

Nervous System Disorders: Somnolence, tingling.

Vascular Disorders: Flushing, hypotension.

Gastrointestinal Disorders: Abdominal pain/cramps, constipation, diarrhea, nausea, vomiting.

Skin and Subcutaneous Tissue Disorders: Erythema, petechiae, pruritus, rash, sweating, urticaria.

Musculoskeletal and Connective Tissue Disorders:

Arthralgia, back pain, myalgia, pain/stiffness in arm, shoulder, or neck.

General Disorders and Administration Site Conditions:

Chills, influenza-like symptoms, injection site ecchymosis, injection site pain, injection site pruritus, irritability, malaise, weakness.

6.2 Postmarketing Experience

In addition to reports in clinical trials, worldwide voluntary reports of adverse events received for ENGERIX-B since market introduction (1990) are listed below. This list includes serious adverse events or events which have a suspected causal connection to components of ENGERIX-B.

The following adverse events have been identified during postapproval use of ENGERIX-B. Because these events are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to the vaccine.

Infections and Infestations: Herpes zoster, meningitis.

Blood and Lymphatic System Disorders: Thrombocytopenia.

Immune System Disorders: Allergic reaction, anaphylactoid reaction, anaphylaxis. An apparent hypersensitivity syndrome (serum sickness-like) of delayed onset has been reported days to weeks after vaccination, including: arthralgia/arthritis (usually transient), fever, and dermatologic reactions such as urticaria, erythema multiforme, ecchymoses, and erythema nodosum.

Nervous System Disorders: Encephalitis, encephalopathy, migraine, multiple sclerosis, neuritis, neuropathy including

ENERGIX-B®

**[Hepatitis B Vaccine (Recombinant)]
Suspension for Intramuscular Injection**

hypoesthesia, paresthesia, Guillain-Barré syndrome and Bell's palsy, optic neuritis, paralysis, paresis, seizures, syncope, transverse myelitis.

Eye Disorders: Conjunctivitis, keratitis, visual disturbances.

Ear and Labyrinth Disorders: Earache, tinnitus, vertigo.

Cardiac Disorders: Palpitations, tachycardia.

Vascular Disorders: Vasculitis.

Respiratory, Thoracic and Mediastinal Disorders:

Apnea, bronchospasm including asthma-like symptoms.

Gastrointestinal Disorders: Dyspepsia.

Skin and Subcutaneous Tissue Disorders: Alopecia,

angioedema, eczema, erythema multiforme including

Stevens-Johnson syndrome, erythema nodosum, lichen

planus, purpura.

Musculoskeletal and Connective Tissue Disorders:

Arthritis, muscular weakness.

General Disorders and Administration Site Conditions:

Injection site reaction.

Investigations: Abnormal liver function tests.

7 DRUG INTERACTIONS

7.1 Concomitant Administration With Vaccines and Immune Globulin

ENGERIX-B may be administered concomitantly with immune globulin.

When concomitant administration of other vaccines or immune globulin is required, they should be given with different syringes and at different injection sites. Do not mix ENGERIX-B with any other vaccine or product in the same syringe or vial.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category C

Animal reproduction studies have not been conducted with ENGERIX-B. It is also not known whether ENGERIX-B can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. ENGERIX-B should be given to a pregnant woman only if clearly needed.

8.3 Nursing Mothers

It is not known whether ENGERIX-B is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when ENGERIX-B is administered to a nursing woman.

8.4 Pediatric Use

Safety and effectiveness of ENGERIX-B have been established in all pediatric age groups. Maternally transferred antibodies do not interfere with the active immune response to the vaccine. [See Adverse Reactions (6) and Clinical Studies (14.1, 14.3, 14.4).]

8.5 Geriatric Use

Clinical studies of ENGERIX-B used for licensure did not include sufficient numbers of subjects 65 years of age and older to determine whether they respond differently from younger subjects. However, in later studies it has been shown that a diminished antibody response and seroprotective levels can be expected in persons older than 60 years of age.⁵

11 DESCRIPTION

ENGERIX-B [Hepatitis B Vaccine (Recombinant)] is a sterile suspension of noninfectious hepatitis B virus surface antigen (HBsAg) for intramuscular administration. It contains purified surface antigen of the virus obtained by culturing genetically engineered *Saccharomyces cerevisiae* cells, which carry the surface antigen gene of the hepatitis B virus. The HBsAg expressed in the cells is purified by several physicochemical steps and formulated as a suspension of the antigen adsorbed on aluminum hydroxide. The procedures used to manufacture ENGERIX-B result in a product that contains no more than 5% yeast protein.

Each 0.5-mL pediatric/adolescent dose contains 10 mcg of HBsAg adsorbed on 0.25 mg aluminum as aluminum hydroxide.

Each 1-mL adult dose contains 20 mcg of HBsAg adsorbed on 0.5 mg aluminum as aluminum hydroxide.

ENGERIX-B contains the following excipients: Sodium chloride (9 mg/mL) and phosphate buffers (disodium phosphate dihydrate, 0.98 mg/mL; sodium dihydrogen phosphate dihydrate, 0.71 mg/mL).

Patient
M-M-R® II (Mumps, Measles, and Rubella)
Generic name
Rubella

This is a summary of
should read it before
vaccine. If you have
after reading this let
care provider. This is
the place of talking
nurse, or other health
care provider can di
your child.

What is M-M-R II

M-M-R II is also kno
Rubella Virus Vaccin
is given as a shot. T
one year old or olde
(rubella), mumps, a
M-M-R II contains v
mumps virus, and i

M-M-R II works by i
you or your child fro

M-M-R II may not p
vaccine. M-M-R II r
rubella once you or
What do I need
mumps, and rub

Measles is also kno
Measles virus can
Measles can give y
The illness can last
It can also cause a
lead to seizures, he
even death.

Mumps can also b
cause fever and he
under your jaw/sw
lumps for several de
the testicles swell
can cause mening
coverings of the br
Rubella is also kno
a mild illness. Rub

Pg. 1

TEAR HERE (Patient Information) TEAR HERE (Patient Information) TEAR HERE (Patient Information)
TEAR HERE (Healthcare Professional Information) TEAR HERE (Healthcare Professional Information) TEAR HERE (Healthcare Professional Information)

M-M-R® II (MEASLES, MUMPS, and RUBELLA VIRUS VACCINE LIVE)

DESCRIPTION

M-M-R® II (Measles, Mumps, and Rubella Virus Vaccine Live) is a live virus vaccine for vaccination against measles (rubella), mumps, and rubella (German measles).

M-M-R II is a sterile lyophilized preparation of (1) ATTENUVAX® (Measles Virus Vaccine Live), a more attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture; (2) MUMPSVAX® (Mumps Virus Vaccine Live), the Jeryl Lynn™ (B level) strain of mumps virus propagated in chick embryo cell culture; and (3) MERUVAX® II (Rubella Virus Vaccine Live), the Wistar RA 27/3 strain of live attenuated rubella virus propagated in WI-38 human diploid lung fibroblasts.^{1,2}

The growth medium for measles and mumps is Medium 199 (a buffered salt solution containing vitamins and amino acids and supplemented with fetal bovine serum) containing SPGA (sucrose, phosphate, glutamate, and recombinant human albumin) as stabilizer and neomycin.

The growth medium for rubella is Minimum Essential Medium (MEM) (a buffered salt solution containing vitamins and amino acids and supplemented with fetal bovine serum) containing recombinant human albumin and neomycin. Sorbitol and hydrolyzed gelatin stabilizer are added to the individual virus harvests.

The cells, virus pools, and fetal bovine serum are all screened for the absence of adventitious agents.

The reconstituted vaccine is for subcutaneous administration. Each 0.5 mL dose contains not less than 1,000 TCID₅₀ (tissue culture infectious doses) of measles virus; 12,500 TCID₅₀ of mumps virus; and 1,000 TCID₅₀ of rubella virus. Each dose of the vaccine is calculated to contain sorbitol (14.5 mg), sodium phosphate, sucrose (1.3 mg), sodium chloride, hydrolyzed gelatin (14.5 mg), recombinant human albumin (<0.3 mg), fetal bovine serum (<1 ppm), other buffer and media ingredients and approximately 25 mcg of neomycin. The product contains no preservative.

Before reconstitution, the lyophilized vaccine is a light yellow compact crystalline plug. M-M-R II, when reconstituted as directed, is clear yellow.

CLINICAL PHARMACOLOGY

Measles, mumps, and rubella are three common childhood diseases, caused by measles virus, mumps virus (paramyxoviruses), and rubella virus (togaviruses), respectively, that may be associated with serious complications and/or death. For example, pneumonia and encephalitis are caused by measles. Mumps is associated with aseptic meningitis, deafness and orchitis; and rubella during pregnancy may cause congenital rubella syndrome in the infants of infected mothers.

The impact of measles, mumps, and rubella vaccination on the natural history of each disease in the United States can be quantified by comparing the maximum number of measles, mumps, and rubella cases reported in a given year prior to vaccine use to the number of cases of each disease reported in 1995. For measles, 894,134 cases reported in 1941 compared to 288 cases reported in 1995 resulted in a 99.97% decrease in reported cases; for mumps, 152,203 cases reported in 1989 compared to 840 cases reported in 1995 resulted in a 99.45% decrease in reported cases; and for rubella, 57,686 cases reported in 1989 compared to 200 cases reported in 1995 resulted in a 99.65% decrease.³

Clinical studies of 284 triple seronegative children, 11 months to 7 years of age, demonstrated that M-M-R II is highly immunogenic and generally well tolerated. In these studies, a single injection of the vaccine induced measles hemagglutination-inhibition (HI) antibodies in 95%, mumps neutralizing antibodies in 98%, and rubella HI antibodies in 98% of susceptible persons. However, a small percentage (1-5%) of vaccinees may fail to seroconvert after the primary dose (see also INDICATIONS AND USAGE, Recommended Vaccination Schedule).

A study⁴ of 6-month-old and 15-month-old infants born to vaccine-immunized mothers demonstrated that, following vaccination with ATTENUVAX, 74% of the 6-month-old infants developed detectable neutralizing antibody (NT) titers while 100% of the 15-month-old infants developed NT. This rate of seroconversion is higher than that previously reported for 6-month-old infants born to naturally immune mothers tested by HI assay. When the 6-month-old infants of immunized mothers were re vaccinated at 15 months, they developed antibody titers equivalent to the 15-month-old vaccinees. The lower seroconversion rate in 6-month-olds has two possible explanations: 1) Due to the limits of the detection level of the assays (NT and enzyme immunoassay [EIA]), the presence of trace amounts of undetectable maternal antibody might interfere with the seroconversion of infants; or 2) The immune system of 6-month-olds is not always capable of mounting a response to measles vaccine as measured by the two antibody assays.

There is some evidence to suggest that infants who are born to mothers who had wild-type measles and who are vaccinated at less than one year of age may not develop sustained antibody levels when later re vaccinated. The advantage of early protection must be weighed against the chance for failure to respond adequately on reimmunization.^{5,6}

Efficacy of measles, mumps, and rubella vaccines was established in a series of double-blind controlled field trials which demonstrated a high degree of protective efficacy afforded by the individual vaccine components.⁷⁻¹² These studies also established that seroconversion in response to vaccination against measles, mumps, and rubella paralleled protection from these diseases.¹³⁻¹⁵

Following vaccination, antibodies associated with protection can be measured by neutralization assays, HI, or ELISA (enzyme linked immunosorbent assay) tests. Neutralizing and ELISA antibodies to measles, mumps, and rubella viruses are still detectable in most individuals 11 to 13 years after primary vaccination.¹⁶⁻¹⁸ See INDICATIONS AND USAGE, Non-Pregnant Adolescent and Adult Females, for Rubella Susceptibility Testing.

The RA 27/3 rubella strain in M-M-R II elicits higher immediate post-vaccination HI, complement-fixing and neutralizing antibody levels than other strains of rubella vaccine.^{19,20} and has been shown to induce a broader profile of circulating antibodies including anti-beta and anti-ota precipitating antibodies.^{20,21} The RA 27/3 rubella strain immunologically simulates natural infection more closely than other rubella vaccine viruses.²²⁻²³ The increased levels and broader profile of antibodies produced by RA 27/3 strain rubella virus vaccine appear to correlate with greater resistance to subclinical reinfection with the wild virus.^{23,24} and provide greater confidence for lasting immunity.

INDICATIONS AND USAGE

Recommended Vaccination Schedule

M-M-R II is indicated for simultaneous vaccination against measles, mumps, and

Hypersensitivity to Eggs

Live measles vaccine and live mumps vaccine are produced in chick embryo cell culture. Persons with a history of anaphylactic, anaphylactoid, or other immediate reactions (e.g., hives, swelling of the mouth and throat, difficulty breathing, hypotension, or shock) subsequent to egg ingestion may be at an enhanced risk of immediate-type hypersensitivity reactions after receiving vaccines containing traces of chick embryo antigen. The potential risk if they have egg allergies that are not anaphylactic, and they should be vaccinated in such cases. Such individuals may be vaccinated with extreme caution, having adequate treatment on hand should a reaction occur (see PRECAUTIONS).¹⁶

However, the AAP has stated, "Most children with a history of anaphylactic reactions to eggs have no untoward reactions to measles or MMR vaccine. Persons are not at increased risk if they have egg allergies that are not anaphylactic, and they should be vaccinated in the usual manner. In addition, skin testing of egg-allergic children with vaccine has not been predictive of which children will have an immediate hypersensitivity reaction. Persons with allergies to chickens or chicken feathers are not at increased risk of reaction to the vaccine."¹⁴

Hypersensitivity to Neomycin

The AAP states, "Persons who have experienced anaphylactic reactions to topically or systemically administered neomycin should not receive measles vaccine. Most often, however, neomycin allergy manifests as a contact dermatitis, which is a delayed-type (cell-mediated) immune response rather than anaphylaxis. In such persons, an adverse reaction to neomycin in the vaccine would be an erythematous, pruritic nodule or papule, 48 to 96 hours after vaccination. A history of contact dermatitis to neomycin is not a contraindication to receiving measles vaccine."¹⁴

Thrombocytopenia

Individuals with current thrombocytopenia may develop more severe thrombocytopenia following vaccination. In addition, individuals who experienced thrombocytopenia with the first dose of M-M-R II (or its component vaccines) may develop thrombocytopenia with repeat doses. Serologic status may be evaluated to determine whether or not additional doses of vaccine are needed. The potential risk to benefit should be carefully evaluated before considering vaccination in such cases (see ADVERSE REACTIONS).

PRECAUTIONS

General

Adequate treatment provisions, including epinephrine injection (1:1000), should be available for immediate use should an anaphylactic or anaphylactoid reaction occur.

Special care should be taken to ensure that the injection does not enter a blood vessel.

Children and young adults who are known to be infected with human immunodeficiency viruses and are not immunosuppressed may be vaccinated. However, vaccinees who are infected with HIV should be monitored closely for vaccine-preventable diseases because immunization may be less effective than for uninfected persons (see CONTRAINDICATIONS).^{4,13}

Vaccination should be deferred for 3 months or longer following blood or plasma transfusions, or administration of immune globulin (human).¹⁴

Excretion of small amounts of the live attenuated rubella virus from the nose or throat has occurred in the majority of susceptible individuals 7 to 28 days after vaccination. There is no confirmed evidence to indicate that such virus is transmitted to susceptible persons who are in contact with the vaccinated individuals. Consequently, transmission through close personal contact, while accepted as a theoretical possibility, is not regarded as a significant risk.²⁵ However, transmission of the rubella vaccine virus to infants via breast milk has been documented (see Nursing Mothers).

There are no reports of transmission of live attenuated measles or mumps viruses from vaccinees to susceptible contacts.

It has been reported that live attenuated measles, mumps and rubella virus vaccines given individually may result in a temporary depression of tuberculin skin sensitivity. Therefore, if a tuberculin test is to be done, it should be administered either before or simultaneously with M-M-R II.

Children under treatment for tuberculosis have not experienced exacerbation of the disease when immunized with live measles virus vaccine.²⁶ No studies have been reported to date of the effect of measles virus vaccines on untreated tuberculous children. However, individuals with active untreated tuberculosis should not be vaccinated.

As for any vaccine, vaccination with M-M-R II may not result in protection in 100% of vaccinees.

The health-care provider should determine the current health status and previous vaccination history of the vaccinee.

The health-care provider should question the patient, parent, or guardian about reactions to a previous dose of M-M-R II or other measles-, mumps-, or rubella-containing vaccines.

Information for Patients

The health-care provider should provide the vaccine information required to be given with each vaccination to the patient, parent, or guardian.

The health-care provider should inform the patient, parent, or guardian of the benefits and risks associated with vaccination. For risks associated with vaccination see WARNINGS, PRECAUTIONS, and ADVERSE REACTIONS.

Patients, parents, or guardians should be instructed to report any serious adverse reactions to their health-care provider who in turn should report such events to the U.S. Department of Health and Human Services through the Vaccine Adverse Event Reporting System (VAERS), 1-800-822-7967.¹⁷

Pregnancy should be avoided for 3 months following vaccination, and patients should be informed of the reasons for this precaution (see INDICATIONS AND USAGE, Non-Pregnant Adolescent and Adult Females, CONTRAINDICATIONS, and PRECAUTIONS, Pregnancy).

Laboratory Tests

See INDICATIONS AND USAGE, Non-Pregnant Adolescent and Adult Females, for Rubella Susceptibility Testing, and CLINICAL PHARMACOLOGY.

Drug Interactions

See DOSAGE AND ADMINISTRATION, Use With Other Vaccines.

Immunosuppressive Therapy

The immune status of patients about to undergo immunosuppressive therapy should be evaluated so that the physician can consider whether vaccination prior to the initiation of treatment is indicated (see CONTRAINDICATIONS and PRECAUTIONS).

The ACIP has stated that "patients with leukemia in remission who have not received chemotherapy for at least 3 months may receive live virus vaccines. Short-term (<2 weeks), low- to moderate-dose systemic corticosteroid therapy, topical steroid therapy (e.g., nasal, skin), long-term alternate-day treatment with low to moderate doses of short-acting systemic steroid, and intra-articular, bursal, or tendon injection of corticosteroids are not immunosuppressive in their usual doses and do not contraindicate the administration of [measles, mumps, or rubella vaccine]."^{23,34,37}

Immune Globulin

Administration of immune globulins concurrently with M-M-R II may interfere with

RE
Sp
Sp
Ur
Or
fol
rel
Nc
su
wi
an
oc
He
Sy
rs
DI
FG
Dc
ou
Se
an
eh
Sc
pr
sp
sf
of
de
de
to
di
wi
vit
IV
Ct
de
sy
M
pr
re
of
ar
ve
br
tr
H
ly
p
ro
Si
th
di
to
St
ar
R
1.
2.
3.
A

INDICATIONS

Local health authorities may recommend measles vaccination of infants between 9 to 12 months of age in outbreak situations. This population may fail to respond to the components of the vaccine. Safety and effectiveness of mumps and rubella vaccine in infants less than 12 months of age have not been established. The younger the infant, the lower the likelihood of seroconversion (see CLINICAL PHARMACOLOGY). Such infants should receive a second dose of M-M-R II between 12 to 15 months of age followed by revaccination at elementary school entry.³⁵

Unnecessary doses of a vaccine are best avoided by ensuring that written documentation of vaccination is preserved and a copy given to each vaccinee's parent or guardian.

Other Vaccination Considerations

Non-Pregnant Adolescent and Adult Females

Immunization of susceptible non-pregnant adolescent and adult females of childbearing age with live attenuated rubella virus vaccine¹⁸ is indicated if certain precautions are observed (see below and PRECAUTIONS). Vaccinating susceptible postpubertal females confers individual protection against subsequently acquiring rubella infection during pregnancy, which in turn prevents infection of the fetus and consequent congenital rubella injury.³²

Women of childbearing age should be advised not to become pregnant for 3 months after vaccination and should be informed of the reasons for this precaution.

The ACIP has stated "It is practical and if reliable laboratory services are available, women of childbearing age who are potential candidates for vaccination can have serologic tests to determine susceptibility to rubella. However, with the exception of premarital and prenatal screening, routinely performing serologic tests for all women of childbearing age to determine susceptibility (so that vaccine is given only to proven susceptible women) can be effective but is expensive. Also, 2 visits to the health-care provider would be necessary — one for screening and one for vaccination. Accordingly, rubella vaccination of a woman who is not known to be pregnant and has no history of vaccination is justifiable without serologic testing — and may be preferable, particularly when costs of serology are high and follow-up of identified susceptible women for vaccination is not assured."³²

Postpubertal females should be informed of the frequent occurrence of generally self-limited arthralgia and/or arthritis beginning 2 to 4 weeks after vaccination (see ADVERSE REACTIONS).

Postpartum Women

It has been found convenient in many instances to vaccinate rubella-susceptible women in the immediate postpartum period (see PRECAUTIONS, Nursing Mothers).

Other Populations

Previously unvaccinated children older than 12 months who are in contact with susceptible pregnant women should receive live attenuated rubella vaccine (such as that contained in monovalent rubella vaccine or in M-M-R II) to reduce the risk of exposure of the pregnant woman.

Individuals planning travel outside the United States, if not immune, can acquire measles, mumps, or rubella and import these diseases into the United States. Therefore, prior to international travel, individuals known to be susceptible to one or more of these diseases can either receive the monovalent vaccine (measles, mumps, or rubella), or a combination vaccine as appropriate. However, M-M-R II is preferred for persons likely to be susceptible to mumps and rubella; and if monovalent measles vaccine is not readily available, travelers should receive M-M-R II regardless of their immune status to mumps or rubella.³⁶

Vaccination is recommended for susceptible individuals in high-risk groups such as college students, health-care workers, and military personnel.^{32,37}

According to ACIP recommendations, most persons born in 1956 or earlier are likely to have been infected with measles naturally and generally need not be considered susceptible. All children, adolescents, and adults born after 1956 are considered susceptible and should be vaccinated, if there are no contraindications. This includes persons who may be immune to measles but who lack adequate documentation of immunity such as: (1) physician-diagnosed measles; (2) laboratory evidence of measles immunity; or (3) adequate immunization with live measles vaccine on or after the first birthday.³⁴

The ACIP recommends that "Persons vaccinated with inactivated vaccine followed within 3 months by live vaccine should be revaccinated with two doses of live vaccine. Revaccination is particularly important when the risk of exposure to wild-type measles virus is increased, as may occur during international travel."³⁴

Post-Exposure Vaccination

Vaccination of individuals exposed to wild-type measles may provide some protection if the vaccine can be administered within 72 hours of exposure. If, however, vaccine is given a few days before exposure, substantial protection may be afforded.^{34,38,39} There is no conclusive evidence that vaccination of individuals recently exposed to wild-type mumps or wild-type rubella will provide protection.^{33,37}

Use With Other Vaccines

See DOSAGE AND ADMINISTRATION, Use With Other Vaccines.

CONTRAINDICATIONS

Hypersensitivity to any component of the vaccine, including gelatin.⁴⁰ Do not give M-M-R II to pregnant females; the possible effects of the vaccine on fetal development are unknown at this time. If vaccination of postpubertal females is undertaken, pregnancy should be avoided for three months following vaccination (see INDICATIONS AND USAGE, Non-Pregnant Adolescent and Adult Females and PRECAUTIONS, Pregnancy).

Anaphylactic or anaphylactoid reactions to neomycin (each dose of reconstituted vaccine contains approximately 25 mcg of neomycin).

Febriile respiratory illness or other active febrile infection. However, the ACIP has recommended that all vaccines can be administered to persons with minor illnesses such as diarrhea, mild upper respiratory infection with or without low-grade fever, or other low-grade febrile illness.⁴¹

Patients receiving immunosuppressive therapy. This contraindication does not apply to patients who are receiving corticosteroids as replacement therapy, e.g., for Addison's disease.

Individuals with blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems.

Primary and acquired immunodeficiency states, including patients who are immunosuppressed in association with AIDS or other clinical manifestations of infection with human immunodeficiency viruses;⁴² cellular immune deficiencies; and hypogammaglobulinemic and dysgammaglobulinemic states. Measles inclusion body encephalitis⁴³ (MIBE), pneumonitis⁴⁴ and death as a direct consequence of disseminated measles vaccine virus infection have been reported in immunocompromised individuals inadvertently vaccinated with measles-containing vaccine.

Individuals with a family history of congenital or hereditary immunodeficiency, until the immune competence of the potential vaccine recipient is demonstrated.

WARNINGS

Due caution should be employed in administration of M-M-R II to persons with a history of cerebral injury, individual or family histories of convulsions, or any other condition in which stress due to fever should be avoided. The physician should be alert to the temperature elevation which may occur following vaccination (see ADVERSE REACTIONS).

to a pregnant woman or can affect reproduction capacity. Therefore, the vaccine should not be administered to pregnant females; furthermore, pregnancy should be avoided for 3 months following vaccination (see INDICATIONS AND USAGE, Non-Pregnant Adolescent and Adult Females and CONTRAINDICATIONS).

In counseling women who are inadvertently vaccinated when pregnant or who become pregnant within 3 months of vaccination, the physician should be aware of the following: (1) In a 10-year survey involving over 700 pregnant women who received rubella vaccine within 3 months before or after conception (of whom 189 received the Wistar RA 27/3 strain), none of the newborns had abnormalities compatible with congenital rubella syndrome;⁴⁵ (2) Mumps infection during the first trimester of pregnancy may increase the rate of spontaneous abortion. Although mumps vaccine virus has been shown to infect the placenta and fetus, there is no evidence that it causes congenital malformations in humans;⁴⁶ and (3) Reports have indicated that contracting wild-type measles during pregnancy enhances fetal risk. Increased rates of spontaneous abortion, stillbirth, congenital defects and prematurity have been observed subsequent to infection with wild-type measles during pregnancy.^{47,48} There are no adequate studies of the attenuated (vaccine) strain of measles virus in pregnancy. However, it would be prudent to assume that the vaccine strain of virus is also capable of inducing adverse fetal effects.

Nursing Mothers

It is not known whether measles or mumps vaccine virus is secreted in human milk. Recent studies have shown that lactating postpartum women immunized with live attenuated rubella vaccine may secrete the virus in breast milk and transmit it to breast-fed infants.⁴⁹ In the infants with serological evidence of rubella infection, none exhibited severe disease; however, one exhibited mild clinical illness typical of acquired rubella.^{49,51} Caution should be exercised when M-M-R II is administered to a nursing woman.

Pediatric Use

Safety and effectiveness of measles vaccine in infants below the age of 6 months has not been established (see also CLINICAL PHARMACOLOGY). Safety and effectiveness of mumps and rubella vaccine in infants less than 12 months of age have not been established.

Geriatric Use

Clinical studies of M-M-R II did not include sufficient numbers of seronegative subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger subjects.

ADVERSE REACTIONS

The following adverse reactions are listed in decreasing order of severity, without regard to causality, within each body system category and have been reported during clinical trials, with use of the marketed vaccine, or with use of monovalent or bivalent vaccine containing measles, mumps, or rubella:

Body as a Whole

Panniculitis; atypical measles; fever; syncope; headache; dizziness; malaise; irritability.

Cardiovascular System

Vasculitis.

Digestive System

Pancreatitis; diarrhea; vomiting; parotitis; nausea.

Endocrine System

Diabetes mellitus.

Hemic and Lymphatic System

Thrombocytopenia (see WARNINGS, Thrombocytopenia); purpura; regional lymphadenopathy; leukocytosis.

Immune System

Anaphylaxis and anaphylactoid reactions have been reported as well as related phenomena such as angioedema and/or edema (including peripheral or facial edema) and bronchial spasm in individuals with or without an allergic history.

Musculoskeletal System

Arthritis; arthralgia; myalgia.

Arthralgia and/or arthritis (usually transient and rarely chronic), and polyneuritis are features of infection with wild-type rubella and vary in frequency and severity with age and sex, being greatest in adult females and least in prepubertal children. This type of involvement as well as myalgia and paresthesia, have also been reported following administration of MERUVAX II.

Chronic arthritis has been associated with wild-type rubella infection and has been related to persistent virus and/or viral antigen isolated from body tissues. Only rarely have vaccine recipients developed chronic joint symptoms.

Following vaccination in children, reactions in joints are uncommon and generally of brief duration. In women, incidence rates for arthritis and arthralgia are generally higher than those seen in children (children: 0-3%, women: 12-26%).^{17,52,53} and the reactions tend to be more marked and of longer duration. Symptoms may persist for a matter of months to years. In adolescent girls, the reactions appear to be intermediate in incidence between those seen in children and in adult women. Even in women older than 35 years, these reactions are generally well tolerated and rarely interfere with normal activities.

Nervous System

Encephalitic; encephalopathy; measles inclusion body encephalitis (MIBE) (see CONTRAINDICATIONS); subacute sclerosing panencephalitis (SSPE); Guillain-Barré Syndrome (GBS); acute disseminated encephalomyelitis (ADEM); febrile convulsions; afebrile convulsions or seizures; ataxia; polyneuritis; polymyopathy; ocular palsies; paresthesia.

Experience from more than 80 million doses of all live measles vaccines given in the U.S. through 1975 indicates that significant central nervous system reactions such as encephalitis and encephalopathy, occurring within 30 days after vaccination, have been temporally associated with measles vaccine very rarely.⁵⁴ In no case has it been shown that reactions were actually caused by vaccine. The Centers for Disease Control and Prevention has pointed out that "a certain number of cases of encephalitis may be expected to occur in a large childhood population in a defined period of time even when no vaccines are administered". However, the data suggest the possibility that some of these cases may have been caused by measles vaccines. The risk of such serious neurological disorders following live measles virus vaccine administration remains far less than that for encephalitis and encephalopathy with wild-type measles (one per two thousand reported cases).

Post-marketing surveillance of the more than 200 million doses of M-M-R and M-M-R II that have been distributed worldwide over 25 years (1971 to 1996) indicates that serious adverse events such as encephalitis and encephalopathy continue to be rarely reported.¹⁷

There have been reports of subacute sclerosing panencephalitis (SSPE) in children who did not have a history of infection with wild-type measles but did receive measles vaccine. Some of these cases may have resulted from unrecognized measles in the first year of life or possibly from the measles vaccination. Based on estimated nationwide measles vaccine distribution, the association of SSPE cases to measles vaccination is about one case per million vaccine doses distributed. This is far less than the association with infection with wild-type measles, 8-22 cases of SSPE per million cases of measles. The results of a retrospective case-controlled study conducted by the Centers for Disease Control and Prevention suggest that the overall effect of measles vaccine has been to protect against SSPE by preventing measles with its inherent higher risk of SSPE.⁵⁵

Cases of aseptic meningitis have been reported to VAERS following measles, mumps, and rubella vaccination. Although a causal relationship between the Urabe strain of mumps vaccine and aseptic meningitis has been shown, there is no evidence to link Jeryl LynnTM mumps vaccine to aseptic meningitis.

Respiratory System

Pneumonia; pneumonitis (see CONTRAINDICATIONS); sore throat; cough; rhinitis.

Skin

Stevens-Johnson syndrome; erythema multiforme; urticaria; rash; measles-like rash; pruritis.

Pg. 2

7002207002

Pg. 3

coverage of the virus, and other...
Rubella is also known as German measles. It is often a mild illness. Rubella virus can cause a mild fever, swollen glands in the neck, pain and swelling in the joints, and a rash that lasts for a short time. It can be very dangerous if a pregnant woman catches it. Women who catch German measles when they are pregnant can have babies who are stillborn. Also, the babies may be blind or deaf, or have heart disease or mental retardation.

Who should not get M-M-R II?
Do not get M-M-R II if you or your child:

- are allergic to any of its ingredients (This includes gelatin or neomycin. See the ingredient list at the end of this leaflet.);
- have a weakened immune system, such as an immune deficiency, an inherited immune disorder, leukemia, lymphoma, or HIV/AIDS;
- take high doses of steroids by mouth or in a shot;
- have a fever higher than 101.3°F (38.5°C);
- are pregnant or plan to get pregnant within the next three months.

What should you tell your health care provider before getting M-M-R II?

- Tell your health care provider if you or your child:
- have or have had any medical problems;
 - have a history of seizures or a brain injury;
 - have received blood or plasma transfusions or human serum globulin;
 - have active tuberculosis that is not treated;
 - take any medicines (This includes non-prescription medicines and dietary supplements.);
 - have any allergies (This includes allergies to neomycin or gelatin.);
 - had an allergic reaction to any other vaccine;
 - are pregnant or plan to become pregnant within the next three months;
 - are breast-feeding.

* Registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. Copyright © 2009 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved.

Pg. 3

TEAR HERE (Patient Information) / TEAR HERE (Patient Information)
Professional Information / TEAR HERE (Healthcare Professional Information)

Local reactions including burning/stinging at injection site; wheal and flare; redness (erythema); swelling; induration; tenderness; vesiculation at injection site.

Special Senses — Ear
Nerve deafness; otitis media.

Special Senses — Eye
Resinitis; optic neuritis; papillitis; retrobulbar neuritis; conjunctivitis.

Urogenital System
Epididymitis; orchitis.

Other
Death from various, and in some cases unknown, causes has been reported rarely following vaccination with measles, mumps, and rubella vaccines; however, a causal relationship has not been established in healthy individuals (see CONTRAINDICATIONS). No deaths or permanent sequelae were reported in a published post-marketing surveillance study in Finland involving 1.5 million children and adults who were vaccinated with M-M-R II during 1982 to 1993.⁵⁸

Under the National Childhood Vaccine Injury Act of 1986, health-care providers and manufacturers are required to record and report certain suspected adverse events occurring within specific time periods after vaccination. However, the U.S. Department of Health and Human Services (DHHS) has established a Vaccine Adverse Event Reporting System (VAERS) which will accept all reports of suspected events.⁴⁷ A VAERS report form as well as information regarding reporting requirements can be obtained by calling VAERS 1-800-922-7897.

DOSE AND ADMINISTRATION
FOR SUBCUTANEOUS ADMINISTRATION
Do not inject intravascularly.

The dose for any age is 0.5 mL administered subcutaneously, preferably into the outer aspect of the upper arm.

The recommended age for primary vaccination is 12 to 15 months.

Re-vaccination with M-M-R II is recommended prior to elementary school entry. See also INDICATIONS AND USAGE, Recommended Vaccination Schedule.

Children first vaccinated when younger than 12 months of age should receive another dose between 12 to 15 months of age followed by re-vaccination prior to elementary school entry.⁵⁹ See also INDICATIONS AND USAGE, Measles Outbreak Schedule.

Immune Globulin (IG) is not to be given concurrently with M-M-R II (see PRECAUTIONS, General and PRECAUTIONS, Drug Interactions).

CAUTION: A sterile syringe free of preservatives, antiseptics, and detergents should be used for each injection and/or reconstitution of the vaccine because these substances may inactivate the live virus vaccine. A 23 gauge, 5/8" needle is recommended.

To reconstitute, use only the diluent supplied, since it is free of preservatives or other antiviral substances which might inactivate the vaccine.

Single Dose Vial — First withdraw the entire volume of diluent into the syringe to be used for reconstitution. Inject all the diluent in the syringe into the vial of lyophilized vaccine, and agitate to mix thoroughly. If the lyophilized vaccine cannot be dissolved, discard. Withdraw the entire contents into a syringe and inject the total volume of reconstituted vaccine subcutaneously.

It is important to use a separate sterile syringe and needle for each individual patient to prevent transmission of hepatitis B and other infectious agents from one person to another.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. M-M-R II, when reconstituted, is clear yellow.

Use With Other Vaccines
M-M-R II should be given one month before or after administration of other live viral vaccines.

M-M-R II has been administered concurrently with VARIVAX® [Varicella Virus Vaccine Live (Oka/Merck)], and PedvaxHIB® [Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate)], using separate injection sites and syringes. No impairment of immune response to individually tested vaccine antigens was demonstrated. The type, frequency, and severity of adverse experiences observed with M-M-R II were similar to those seen when each vaccine was given alone.

Routine administration of DTP (diphtheria, tetanus, pertussis) and/or OPV (oral poliovirus vaccine) concurrently with measles, mumps and rubella vaccines is not recommended because there are limited data relating to the simultaneous administration of these antigens.

However, other schedules have been used. The ACIP has stated "Although data are limited concerning the simultaneous administration of the entire recommended vaccine series (i.e., DTP [or DTWP], IPV [or OPV], Hib with or without Hepatitis B vaccine, and varicella vaccine), data from numerous studies have indicated no interference between routinely recommended childhood vaccines (either live, attenuated, or killed). These findings support the simultaneous use of all vaccines as recommended."⁴²

HOW SUPPLIED
No. 4681 — M-M-R II is supplied as follows: (1) a box of 10 single-dose vials of lyophilized vaccine (package A), NDC 0006-4681-00, and (2) a box of 10 vials of diluent (package B). To conserve refrigerator space, the diluent may be stored separately at room temperature.

Storage
To maintain potency, M-M-R II must be stored between -58°F and -48°F (-50°C to +8°C). Use of dry ice may subject M-M-R II to temperatures colder than -58°F (-50°C). Protect the vaccine from light at all times, since such exposure may inactivate the viruses.

Landes, R.D.; Bass, J.W.; Millunchick, E.W.; Detgen, W.J.: Neonatal rubella following postpartum maternal immunization, J. Pediatr. 97:465-467, 1980.

Lerman, S.J.: Neonatal rubella following postpartum maternal immunization, J. Pediatr. 96:688, 1981. (Letter)

Gershon, A.; et al: Live attenuated rubella virus vaccine: comparison of responses to HPV-77-DE5 and RA 27/3 strains, Am. J. Med. Sci. 278(2): 95-97, 1980.

Weibel, R.E.; et al: Clinical and laboratory studies of live attenuated RA 27/3 and HPV-77-DE rubella virus vaccines, Proc. Soc. Exp. Biol. Med. 165:44-49, 1980.

CDC. Important Information about Measles, Mumps, and Rubella, and Measles, Mumps, and Rubella Vaccines. 1980. 1983.

CDC. Measles Surveillance, Report No. 11, p. 14, September 1982.

Peltola, H.; et al: The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two dose vaccination program. N. Engl. J. Med. 321: 1397-1402, 1994.

Eberhart-Phillips, J.E.; et al: Measles in pregnancy: a descriptive study of 58 cases. Obstetrics and Gynecology, 82(5): 797-801, November 1993.

Jespersen, C.S.; et al: Measles as a cause of fetal defects: A retrospective study of ten measles epidemics in Greenland. Acta Paediatr Scand. 66: 367-372, May 1977.

Measles, Mumps, and Rubella — Vaccine Use and Strategies for Elimination of Measles, Rubella, and Congenital Rubella Syndrome and Control of Mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR 47(RR-8): May 22, 1998.

Bittum, A.; et al: Measles Inclusion Body Encephalitis Caused by the Vaccine Strain of Measles Virus. Clin. Infect. Dis. 22: 855-861, 1995.

Angel, J.B.; et al: Vaccine Associated Measles Pneumonitis in an Adult with AIDS. Annals of Internal Medicine, 129: 104-106, 1998.

Dist. by:
Merck Sharp & Dohme Corp., a subsidiary of
MERCK & CO., INC.
Whitehouse Station, NJ 08889, USA

For patent information: www.merck.com/product/patent/home.html

Copyright © 2014 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved.
Revised: 02/2014
uspi-v205c-1-1402-003

7002207002

Polio Vaccine
IPOL by Sanofi Pasteur

pg. 1

with DTP in two sites (3) or combined (4) with
IPOL vaccine at 2, 4, and 6 months
and 93% (Type 2) and 92% to 94% (Type 3) of
100% (Type 2) and 92% to 94% (Type 3) of

L vaccine or a combination vaccine containing
IPOL vaccine, 2 or 3 doses are given
at 1, 2, and 3 months of age. After the second age
test for detectable serum neutralizing antibody
: to 100% (Type 2) and 94% to 100% (Type 3)
e given during the first year of life, post-dose
00% (Type 2) and 92% to 100% (Type 3) and
is given during the second year of life (14 to
combination vaccine containing IPOL vaccine
dose given during the second year of life, the
96% and 97% against poliovirus Type 1, 2, and
3, respectively. The vaccine is given to all
infant young adults from a Swedish IPV only
encapsulating antibody for at least 10 years to all

the poliovirus and get and reduce poliovirus
serum neutralizing antibody (SNA) levels
months 1, 6, 16, 41, 61, 121, 181, 91, 201, 211
with IPV (1, 5) (23) (24) (25) (26) and that this
ation of IPOL vaccine. (27) It is expected that an
opments and contacts compared to a schedule
1 (for young at 6 weeks of age) children and
as 7 (Type 1, 2, and 3) (28)

Children Incompletely Immunized
Children of all ages should have their immunization status reviewed and be considered for supplemental immunization as follows: 1-year intervals between doses longer than those recommended for routine primary immunization; 2-year intervals between doses as long as a final total of four doses is achieved. (See **DOSEAGE AND ADMINISTRATION** section.)

General Precautions
Routine primary poliovirus vaccination of adults (generally those 18 years of age or older) residing in the US is not recommended. Unimmunized adults who are potentially exposed to wild poliovirus and have not been adequately immunized should receive polio vaccination in accordance with the schedule given in the **DOSEAGE AND ADMINISTRATION** section. (28)

Persons with previous wild poliovirus disease who are incompletely immunized or unimmunized should receive supplemental immunization with IPOL vaccine. Persons with previous wild poliovirus disease who are immunized with IPOL vaccine should receive supplemental immunization with IPOL vaccine. The following categories of adults are at an increased risk of exposure to wild poliovirus: (28) (31)

- Travelers to regions or countries where poliovirus is endemic or epidemic.
- Health-care workers in close contact with patients who may be excreting poliovirus.
- Household contacts of specific populations known to have disease caused by wild poliovirus.

IMMUNODEFICIENCY AND ALTERED IMMUNE STATUS
IPOL vaccine should be used in all patients with immunodeficiency diseases and members of each patient's household when vaccination of such persons is indicated. This includes patients with congenenetic HIV infection, AIDS or AIDS-related Complex, severe combined immunodeficiency, hypogammaglobulinemia, or agammaglobulinemia; altered immune status due to diseases such as leukemia, lymphoma, or generalized malignancy; or an immunosuppressive drug regimen including corticosteroids, cytotoxic drugs, or radiation therapy. The immunologic response to IPOL vaccine in immunodeficient and immunoglobulin could be impaired, and patients with an altered immune status may or may not develop a protective response against paralytic poliovirus after administration of IPV. (32)

As with any vaccine, vaccination with IPOL vaccine may not protect 100% of individuals.

Use with other vaccines: refer to **DOSEAGE AND ADMINISTRATION** section for this information.

CONTRAINDICATIONS
IPOL vaccine is contraindicated in persons with a history of hypersensitivity to any component of the vaccine or to any of the following: gelatin, egg protein, antibiotics, or other substances. No further doses should be given if anaphylaxis or anaphylactic shock occurs within 24 hours of administration of one dose of vaccine.

Vaccination of persons with an acute, febrile illness should be deferred until after recovery, however, minor febrile illnesses, such as mild upper respiratory infection, with or without low grade fever, are not reasons for postponing vaccine administration.

WARNINGS
Neurotoxicity, encephalomyelitis, polyneuritis, B₂ phenoxypoliovirus, and formolins are used in the production of this vaccine. Although purification procedures eliminate measurable amounts of these substances, traces may be present (see **DESCRIPTION** section), and allergic reactions may occur in persons sensitive to these substances (see **CONTRAINDICATIONS** section).

Special DTP doses: refer to **DOSEAGE AND ADMINISTRATION** section for information on separate sites or combined sites. DTP doses should be given in accordance with administration of DTP doses. (1) Local reactions are usually mild and transient in nature.

Although no causal relationship between IPOL vaccine and Guillain-Barre Syndrome (GBS) has been established, (28) GBS has been temporally related to administration of another inactivated poliovirus vaccine. Deaths have been reported in temporal association with the administration of IPV (see **ADVERSE REACTIONS** section).

PRECAUTIONS

GENERAL
Persons receiving any vaccine, all having practitioners should be taken to prevent adverse reactions. The inclusion of the patient's history with respect to possible sensitivity to the vaccine or similar vaccines.

Health-care providers should question the patient, parent, or guardian about reactions to a previous dose of this product, or similar product.

Health-care providers should question the patient, parent, or guardian about reactions to a previous dose of this product, or similar product.

Health-care providers should obtain the previous immunization history of the vaccinee, and inquire about the current health status of the vaccinee.

Immunodeficient patients or patients under immunosuppressive therapy may not develop a protective immune response to paralytic poliovirus after administration of IPOL vaccine.

Administration of IPOL vaccine to patients with HIV (33) (34) (35)

Special care should be taken to ensure that the injection does not enter a blood vessel.

INFORMATION FOR PATIENTS
Patients, parents, or guardians should be instructed to report any serious adverse reactions to their health-care provider.

The health-care provider should inform the patient, parent, or guardian of the benefits and risks of the vaccine.

The health-care provider should inform the patient, parent, or guardian of the importance of completing the vaccine series.

The health-care provider should provide the Vaccine Information Statements (VIS) which are required to be given with each immunization.

DRUG INTERACTIONS
There are no known interactions of IPOL vaccine with drugs or foods. Concurrent administration of other parenteral vaccines, with separate syringes at separate sites, is not contraindicated. The first two doses of IPOL vaccine may be administered at separate sites using separate syringes concomitantly with other parenteral vaccines, with separate syringes (36) and separate syringes (36). From historical data on the safety of IPOL vaccine, no interference has been observed on the immunological end points accepted for clinical protection (1) (16) (36) (See **DOSEAGE AND ADMINISTRATION** section).

IPOL vaccine should be given to persons receiving immunosuppressive therapy, an adequate immunologic response may not be obtained (See **PRECAUTIONS** section).

CANCERGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY
Long-term studies in animals to evaluate carcinogen, potential or impairment of fertility have not been conducted.

PREGNANCY CATEGORY C
Long-term studies in animals have not been conducted with IPOL vaccine. It is also not known whether IPOL vaccine administered to pregnant women may cause fetal harm or affect reproduction capacity. IPOL vaccine should be given to a pregnant woman only if clearly needed.

